It is extraordinary to contemplate how, six short years ago, during the COVID-19 pandemic, the entire world faced challenging shortages of medical supplies and equipment. Ethylene oxide is a gas that is naturally ubiquitous in the air around us, and which occurs naturally in our bodies. The FDA therefore raised major concerns over the effect that the EPA’s proposal would have on the U.S. medical supply chain, which the environmental agency essentially ignored when adopting the 2024 regulation. There were concerns that medical sterilizers would need to raise prices to cover the higher costs, or that medical equipment would now need to be imported to fill the gaps, thereby undermining U.S. medical supply chains. Better yet, the EPA has proposed to rescind the 2024 rule that threatened to impose these prohibitive requirements on the U.S. medical sterilization industry in the first place.